Discover and read the best of Twitter Threads about #ECCMID2023
Most recents (15)
Für mich eines der Highlights vom #ECCMID2023: Plazebo-kontrollierte doppelt-blinde Studie der @UniofOxford zu Post-COVID Fatigue.
Signifikante Verbesserung der Fatigue durch AXA1125 (ein Peptide mit Metabolismus-modulierenden Eigenschaften).
Signifikante Verbesserung der Fatigue durch AXA1125 (ein Peptide mit Metabolismus-modulierenden Eigenschaften).
Die Studie verfehlte den primären Endpunkt (verbesserte mitochondrial Atmung gemessen als verkürzte Phosphokreatinin-Recovery Time in der MRS), aber erreichte sek. Endpunkte (verbesserte Fatigue-Scores). V.a zeigten viele Probanden ein positives Ansprechen
AXA1125 ist schon in anderen Indikationen getestet worden & zeigt ein gutes Sicherheitsprofil.
Jetzt braucht es eine größere Studie & evtl. bessere Patientenselektion.
Aber die Daten machen Hoffnung, dass ein Teil der Betroffenen von dieser Therapie profitieren könnte.
Jetzt braucht es eine größere Studie & evtl. bessere Patientenselektion.
Aber die Daten machen Hoffnung, dass ein Teil der Betroffenen von dieser Therapie profitieren könnte.
🚨🚨New #SIRENstudy preprint 🚨🚨
Not yet peer reviewed.
papers.ssrn.com/sol3/papers.cf…
A 🧵 1/n
@victoria_jhall @bealelab @SMHopkins
Not yet peer reviewed.
papers.ssrn.com/sol3/papers.cf…
A 🧵 1/n
@victoria_jhall @bealelab @SMHopkins
First up thank you to the amazing participants in #SIRENstudy 🙏 Without you, no study. NHS staff continuing to go above and beyond in really challenging times 🤩 #notAllHeroesWearCapes
And, of course, our thanks to the NHS sites across all 4 countries!
2/n
And, of course, our thanks to the NHS sites across all 4 countries!
2/n
We wanted to find the correlate of protection (CoP) against Delta infection.
No study so far has managed this.
Aficionados might want to skip ahead: papers.ssrn.com/sol3/papers.cf…
3/n
No study so far has managed this.
Aficionados might want to skip ahead: papers.ssrn.com/sol3/papers.cf…
3/n
New drugs against GNB by Ursula Theuretzbacher #ECCMID2023
In Malaysia, we only have Cefta-avi for resistant GNB infections!
We hope @SHIONOGI_JP will include Malaysia in the list of countries for generic cefiderocol- a project by @gardp_amr
@KKMPutrajaya @DrZalihaMustafa
In Malaysia, we only have Cefta-avi for resistant GNB infections!
We hope @SHIONOGI_JP will include Malaysia in the list of countries for generic cefiderocol- a project by @gardp_amr
@KKMPutrajaya @DrZalihaMustafa
These are the drugs that are recently approved and we have none of these locally
We can only use Fe-troja(n)/Cefiderocol by @SHIONOGI_JP under the compassionate use program, and the drug is flown all the way from Europe
The cost is huge and our patients can rarely afford it
We can only use Fe-troja(n)/Cefiderocol by @SHIONOGI_JP under the compassionate use program, and the drug is flown all the way from Europe
The cost is huge and our patients can rarely afford it
Again, the same table:
The red ones are called DBO/Diazabicyclooctanes. They have an added PBP activity in addition to BLI activity
Boronates have extended BLI activity (MBL)
The green one is the Tazobactam analogue
Here is an excellent podcast on these: asm.org/Podcasts/Edito…
The red ones are called DBO/Diazabicyclooctanes. They have an added PBP activity in addition to BLI activity
Boronates have extended BLI activity (MBL)
The green one is the Tazobactam analogue
Here is an excellent podcast on these: asm.org/Podcasts/Edito…
#ECCMID2023 Tom Harrison, keynote masterclass in the management in cryptococcal meningitis: how a wood-rot fungus leads to such serious disease; major burden of disease, >100,000 deaths /year, 19% of AIDS related death, >60% mortality in the past
No dec. in cases in Sub-Saharan Africa outside SA, despite ART; IDSA standard of 2w AmpB + 5-FC based on studies from 1990s e.g. nejm.org/doi/full/10.10… but AmpB is hard to find in many countries, needs IV, hard to administer and monitor - Flucon monotherapy not as effective
Fluconazole just has much less early fungicidal activity vs AmpB - not helped much with higher doses, seem 1200mg or if adding 5-FC does approach efficacy of AmpB and possible improved survival - helps prevents flucon-R emergence via heteroresistance (@DrNeilStone !)
#ECCMID2023 1/3. Alex Soriano: PO the new IV? Need to consider oral bioavailability, pathogen MICs, delays to Cmax, inter-individual variability in BA etc
2/3 Numerous RCTs now demonstrate short course therapy is adequate for most syndromes; RCT of oral switch in severe CAP is safe and reduced LoS pubmed.ncbi.nlm.nih.gov/17090560/
3/3 Early oral switch in non-critically ill febrile patients: The acute phase of infection does not influence the exposure or PTA for PO amoxicillin or cipro
pubmed.ncbi.nlm.nih.gov/36433818/
pubmed.ncbi.nlm.nih.gov/36433818/
Fairytales or reality, checking some eminence paradigms for treatment of severe infections
#ECCMID2023
#ECCMID2023
Kill fast! These infections must be treated with a "bactericidal" antibiotic
Beatrice Grabein, Germany
Clindamycin is bad for invasive MRSA infection
journals.asm.org/doi/full/10.11…
Beatrice Grabein, Germany
Clindamycin is bad for invasive MRSA infection
journals.asm.org/doi/full/10.11…
👨⚕️Very nice session on issues of complicated UTIs by Dr. Aurelien Dinh. #ECCMID2023
- It's believed that cUTI is more difficult to treat
- Maybe higher rate of resistance
- Need higher dosage or prolonged treatment?
- It's believed that cUTI is more difficult to treat
- Maybe higher rate of resistance
- Need higher dosage or prolonged treatment?
Modern definitions of cUTIs... #ECCMID2023
Does "complicated" definition apply to all kinds of UTIs? Uncomplicated pyelonephritis?? 🤨 #ECCMID2023
🛌Fantastic presentation by Dr. Isabel Spriet on #antifungal dosing, which included several patient case discussions! #ECCMID2023
- Major clinical uses of antifungals
- Focus is on invasive fungal infections
- Major clinical uses of antifungals
- Focus is on invasive fungal infections
Standard dosing of antifungals are based on patient PK, fungal pathogen PD, and ideal PK-PD targets... #ECCMID2023
Translational research model for antifungal drug development involves pre-clinical PK-PD target determination followed by clinical trials... #ECCMID2023
Polymyxins and carbapenems: their place in the treatment of MDR Gram-negative infection today
#ECCMID2023
This a very relevant talk for us in Southeast Asia (exc Singapore)
@alif82 @SyamhaninA @fikreeahmad @shaharudeen @GSRajahram @stevenlimcl @SazaliBasri @HanzHc
#ECCMID2023
This a very relevant talk for us in Southeast Asia (exc Singapore)
@alif82 @SyamhaninA @fikreeahmad @shaharudeen @GSRajahram @stevenlimcl @SazaliBasri @HanzHc
Trish Peel from 🇦🇺🐨🦘 : ASAP trial of Abx prophylaxis for prosthetic joint surgery. #ECCMID2023 pubmed.ncbi.nlm.nih.gov/31685516/
Inc. rates of MRSA and MR-S. epi , need to add glycopeptide to prophylaxis? Needed an RCT. Double blinded superiority RCT undergoing joint replacement / revision surgery. Imbedded staphylococcal carriage study (nasal/skin swabs); primary outcome SSI up to 90d
Sample size 4320 pts based on 5% vs 3% risk (i.e 2% reduction with intervention); COVID disrupted a bit; slightly high MRSA carriage in placebo; knee surgery infection 3.7% vs 5.7% in placebo vs. vanco (RR 1.52; 95% confidence interval 1.04 to 2.23; p value 0.031)
He talked about his evolution when he came back from the US and the UK
He needed to learn about the cultures in India
This includes antibiotics as a one-size-fits-all remedy
He captured the issues of empiric therapies - one empiric regimen after another.
He needed to learn about the cultures in India
This includes antibiotics as a one-size-fits-all remedy
He captured the issues of empiric therapies - one empiric regimen after another.
Tricks and tips for the infectious diseases consultant by Esther CALBO, Spain at #ECCMID2023
Risk of death for ID physicians from "womb to tomb."
Risk of death for ID physicians from "womb to tomb."
Our role is essential (ID consult can reduce the risk of death)
However, we must know how to sell our importance to the hospital suite
However, we must know how to sell our importance to the hospital suite
Solicited interventions are more welcomed than the nonsolicited ones
Does AMR increase the risk for bacteremia recurrence?
Session: Impact of antimicrobial resistance on the risk of recurrence after community-onset bacteremia
Speaker: Salam Abarra
#ECCMID2023
Session: Impact of antimicrobial resistance on the risk of recurrence after community-onset bacteremia
Speaker: Salam Abarra
#ECCMID2023
EC, KP, And SA were chosen as they were the main etiologies of CA-bacteremia
Risk factors for persistent bacteremia in patients with GNB BSI: an SR with meta-analysis
Do you do a FUBC in GNB patients?
@alif82 (something that might interest you)
QnA: How freq was the FUBC in these studies?
Variable ways of FUBC in all the included studies
#ECCMID2023
Do you do a FUBC in GNB patients?
@alif82 (something that might interest you)
QnA: How freq was the FUBC in these studies?
Variable ways of FUBC in all the included studies
#ECCMID2023
Methodology 1
Methodology 2
SAFO Trial in #ECCMID2023
Main findings:
Shorted duration of bacteremia
But similar mortality
As per predicted by @DrToddLee
QnA:
How many were complicated vs. unc.
The majority were unc.
Sec outcome of persistent bacteremia was defined as bacteremia > 72H
Main findings:
Shorted duration of bacteremia
But similar mortality
As per predicted by @DrToddLee
QnA:
How many were complicated vs. unc.
The majority were unc.
Sec outcome of persistent bacteremia was defined as bacteremia > 72H
Why Fosfomycin?
Methodology:
